|
Match
|
Document |
Document Title |
|
|
US20140205621 |
CANINE CORONAVIRUS VACCINE
A new pantropic canine coronavirus (CCoV) strain, having reduced pathogenicity, and capable of eliciting an immune response, is described. |
|
|
US20110045023 |
Recombinant RSV Virus Expression Systems And Vaccines
The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in... |
|
|
US20150093404 |
PCV2 ORF2 PROTEIN VARIANT AND VIRUS LIKE PARTICLES COMPOSED THEREOF
Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2... |
|
|
US20120282217 |
FOOT AND MOUTH DISEASE VIRUS (FMDV) CONSENSUS PROTEINS, CODING SEQUENCES THEREFOR AND VACCINES MADE THEREFROM
Provided herein is a nucleic acid comprising consensus amino acid sequence of foot-and-mouth disease FMDV VP1-4 coat proteins of FMDV subtypes A, Asia 1, C, O, SAT1, SAT2, and SAT3 as well as... |
|
|
US20140162340 |
SYNTHETIC HEPATITIS C GENOME AND METHODS OF MAKING AND USE
Synthetic representative HCV subtypes, including a 1a and 1b genome, dubbed Bole1a and Bole1b, are provided using an inventive method of Bayesian phylogenetic tree analysis, ancestral sequence... |
|
|
US20110171250 |
Synthetic Gene Construct Coding for an HIV1 GAG and Use Thereof for Obtaining Anti-HIV-1 Vaccines
The invention relates to a synthetic gene coding for the Gag protein of the human immunodeficiency virus HIV-1. Said gene may optionally be fused with one or more other HIV sequences. The... |
|
|
US20140010885 |
SELF-ASSEMBLING NANOPARTICLE DRUG DELIVERY SYSTEM
A self-assembling nanoparticle drug delivery system for the delivery of various bioactive agents including peptides, proteins, nucleic acids or synthetic chemical drugs is provided. The... |
|
|
US20120177675 |
Chimaeric Protein
The present invention provides a chimaeric coronavirus S protein which is based on an S protein from a coronavirus strain with restricted tissue tropism, but which comprises at least part of the... |
|
|
US20130345400 |
IDENTIFICATION OF A HUMAN GYROVIRUS AND APPLICATIONS
The present invention relates to HGyV, a human gyrovirus related to the chicken anemia virus (CAV). The present invention also relates to a new proteins encoded by HGyV, which proteins display... |
|
|
US20110189232 |
RECOMBINANT HUMAN PARAINFLUENZA TYPE 1 VIRUSES (HPIV1s) CONTAINING MUTATIONS IN OR DELETION OF THE C PROTEIN ARE ATTENUATED IN AFRICAN GREEN MONKEYS AND IN CILIATED HUMAN AIRWAY EPITHELIAL CELLS AND ARE POTENTIAL VACCINE CANDIDATES FOR HPIV1
Two recently characterized live attenuated HPIV1 vaccine candidates, rHPIV1-CR84G/Δ170HNT553ALY942A and rHPIV1-CR84G/Δ170HN-T553ALΔ1710-11, which contain temperature sensitive (ts) attenuating... |
|
|
US20140294892 |
CONSTRUCTION OF WEST NILE VIRUS AND DENGUE VIRUS CHIMERAS FOR USE IN A LIVE VIRUS VACCINE TO PREVENT DISEASE CAUSED BY WEST NILE VIRUS
The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines. |
|
|
US20110189159 |
METHODS AND COMPOSITIONS FOR PROTEIN DELIVERY
The present invention provides methods and compositions for protein delivery. The invention features virus like particles, methods of making virus like particles and methods of using virus like... |
|
|
US20110008835 |
SYSTEM FOR THE HETEROLOGOUS EXPRESSION OF A VIRAL PROTEIN IN A CILIATE HOST CELL
The present invention relates to a system for the heterologous expression of a viral protein or a fragment thereof, said system comprising a) a ciliate host cell,b) at least one cDNA encoding for... |
|
|
US20140010840 |
RECOMBINANT MUMPS VIRUS VACCINE
The present invention provides the complete genomic sequence of the epidemic mumps virus (MuV) strain MuVIowa/us/06. Further, a reverse genetics system was constructed and used to rescue... |
|
|
US20140086947 |
VACCINES FOR HSV-2
Compositions of recombinant HSV-2 proteins and an agonist of the innate immune system, such as an adjuvant, are provided as a vaccine. Proteins include an envelope glycoprotein and a structural... |
|
|
US20120263751 |
Recombinant Measles Virus Useful as a Bivalent Vaccine Against Measles and Nipah Infections
Provided herein is a vaccine which is safe and effective against Nipah virus infection and a vector which is used in the manufacture of this vaccine and to provide a bivalent vaccine which... |
|
|
US20130209499 |
VACCINES FOR USE IN THE PROPHYLAXIS AND TREATMENT OF INFLUENZA VIRUS DISEASE
Provided herein are polypeptides comprising portions of the influenza virus hemagglutinin, compositions comprising such polypeptides that can be used as immunogens in vaccines and methods of their... |
|
|
US20110021611 |
EFFICIENT CELL CULTURE SYSTEM FOR HEPATITIS C VIRUS GENOTYPE 5A
The present inventors developed 5a/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and all of or part of NS2 were replaced by the corresponding genes of the... |
|
|
US20110287050 |
RECOMBINANT KOI HERPESVIRUS (KHV) OR CYPRINID HERPESVIRUS 3 (CYHV-3) AND A VACCINE FOR THE PREVENTION OF A DISEASE CAUSED BY KHV/CYHV-3 IN CYPRINUS CARPIO CARPIO OR CYPRINUS CARPIO KOI
The present invention refers to a recombinant koi herpesvirus (KHV) or Cyprinid herpesvirus 3 (CyHV-3), which is immunogenic in fish, preferably in carps, more preferably in Cyprinus carpio, and... |
|
|
US20140147460 |
TRUNCATED L1 PROTEIN OF HUMAN PAPILLOMAVIRUS TYPE 33
The present invention relates to a truncated L1 protein of Human Papillomavirus (HPV) Type 33, a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising... |
|
|
US20120288520 |
Recombinant Flavivirus Vaccines
The invention provides recombinant flavivirus vaccines that can be used in the prevention and treatment of flavivirus infection. The vaccines of the invention contain recombinant flaviviruses... |
|
|
US20150247163 |
COMPOSITIONS AND SYSTEMS FOR CONFERRING DISEASE RESISTANCE IN PLANTS AND METHODS OF USE THEREOF
Compositions, systems and methods are provided for conferring disease resistance to plant pathogens that use proteases to target plant substrate proteins inside plant cells. Briefly, the... |
|
|
US20120315295 |
Development of a Marker Foot and Mouth Disease Virus Vaccine Candidate That is Attenuated in the Natural Host
We have generated novel molecularly marked FMDV A24LL3DYR and A24LL3BPVKV3DYR vaccine candidates. The mutant viruses contain a deletion of the leader coding region (LL) rendering the virus... |
|
|
US20110107466 |
VIRUS VECTOR AND USE THEREOF
It is intended to provide a polynucleotide comprising a viral base sequence, the viral base sequence containing: a first base sequence encoding a viral replication protein, and a second base... |
|
|
US20150086580 |
RATIONAL VACCINE DESIGN FOR HEPATITIS C VIRUS
Compositions and methods are provided relating to HCV E2 protein and modifications thereto which enhance the immunogenicity of the protein for vaccine development with respect to the generation of... |
|
|
US20130115234 |
Ectodomains of Influenza Matrix 2 Protein, Expression System, and Uses Thereof
The present invention provides a polynucleotide, polypeptide, recombinant modified vaccinia virus Ankara (rMVA) and related vaccine compositions and methods useful in the prevention and treatment... |
|
|
US20120100116 |
NEURON GENERATION, REGENERATION AND PROTECTION
The invention demonstrates that, contrary to apoptotic rabies virus G proteins, certain non-apoptotic rabies virus G proteins, such as the G protein of the CVS-NIV strain, have a neurite outgrowth... |
|
|
US20110206724 |
HEPATITIS VIRUS CORE PROTEINS AS VACCINE PLATFORMS AND METHODS OF USE THEREOF
The present invention relates to hepatitis virus core proteins and nucleic acids. In particular, the present invention provides compositions and methods comprising recombinant hepatitis virus core... |
|
|
US20130071419 |
UNIVERSAL DENGUE VIRUS SEQUENCES AND METHODS OF USE
Disclosed herein are computationally optimized broadly reactive dengue virus E polypeptide sequences for DENV-1, DENV-2, DENV-3 and DENV-4. Also disclosed are dengue virus E protein fragments... |
|
|
US20140037665 |
PESTIVIRUS SPECIES
The application relates to a pestivirus, designated PMC virus, that is associated with porcine myocarditis syndrome, and the gene and protein sequences derived therefrom. The application further... |
|
|
US20120237519 |
PESTVIRUS SPECIES
The application relates to a pestivirus, designated PMC virus, that is associated with porcine myocarditis syndrome, and the gene and protein sequences derived therefrom. The application further... |
|
|
US20120034256 |
HCV VACCINES AND METHODS FOR USING THE SAME
Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1 a/1 b NS3 and NS4A. Pharmaceutical... |
|
|
US20130017572 |
CODON MODIFIED POLYNUCLEOTIDE SEQUENCES FOR ENHANCED EXPRESSION IN A HOST SYSTEM
Synthetic DNA molecules encoding various HPV proteins are provided. The codons of the synthetic molecules are designed so as to use the codons that preferentially increase expression of the... |
|
|
US20110014232 |
CHIMERIC FOOT AND MOUTH DISEASE VIRUSES
Foot and mouth disease (FMD) viruses which are able to grow on BHK-21 cells in suspension are described herein. The new viruses are recombinant chimeric viruses formed by replacing the outer... |
|
|
US20120107338 |
IDENTIFICATION OF A NOVEL RETROVIRUS IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
Methods for producing an immune response to a benign prostatic hyperplasia (BPH) virus are disclosed herein. In several examples, the immune response is a protective immune response. In additional... |
|
|
US20150166612 |
Vaccines And Methods For Using The Same
Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1a, including for example, NS4B, NS5A and... |
|
|
US20120093863 |
HCV VACCINES AND METHODS FOR USING THE SAME
Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1a, including for example, NS4B, NS5A and... |
|
|
US20140294771 |
Adeno-Associated Virus Virions with Variant Capsid and Methods of Use Thereof
The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via... |
|
|
US20110052626 |
LEPORIPOXVIRUS-DERIVED VACCINE VECTORS
The invention relates to modified leporipoxyinises expressing a chimeric envelope protein resulting from the fusion of an envelope protein of mature intracellular virions or of an envelope protein... |
|
|
US20120045467 |
INFLUENZA VIRUS VACCINE COMPOSITION AND METHODS OF USE
The present invention is directed to enhancing the immune response of a human in need of protection against IV infection by administering in vivo, into a tissue of the human, at least one... |
|
|
US20120128717 |
INFLUENZA VIRUS VACCINE COMPOSITION AND METHODS OF USE
The present invention is directed to compositions and methods for enhancing the immune response of a human in need of protection against influenza virus (IV) infection by administering in vivo,... |
|
|
US20150104475 |
COMPOSITIONS AND METHODS RELATED TO VIRAL VACCINES
Provided herein are methods and compositions relating to Infectious Bursal Disease Virus (IBDV), and vaccines for treatment and prevention thereof. |
|
|
US20120231028 |
POLYVALENT VACCINE
The present invention relates, in general, to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to... |
|
|
US20120121631 |
POLYVALENT VACCINE
The present invention relates, in general, to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to... |
|
|
US20110301328 |
POLYVALENT VACCINE
The present invention relates, in general, to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to... |
|
|
US20110150915 |
POLYVALENT VACCINE
The present invention relates, in general, to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to... |
|
|
US20130259869 |
REARRANGED TT VIRUS MOLECULES FOR USE IN DIAGNOSIS, PREVENTION AND TREATMENT OF CANCER AND AUTOIMMUNITY
The present invention relates to rearranged molecules of (a) a specific TT virus sequence and (b) a nucleotide sequence encoding a polypeptide showing homology to mammalian proteins associated... |
|
|
US20120064169 |
MULTIPLE ANTIGEN DELIVERY SYSTEM USING HEPATITIS E VIRUS-LIKE PARTICLE
This invention provides a peptide/nucleic acid composition for oral/mucosal, dual-modal activation of immune protection systems. |
|
|
US20110294194 |
EFFICIENT CELL CULTURE SYSTEM FOR HEPATITIS C VIRUS GENOTYPE 2B
The present inventors developed hepatitis C virus 2b/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and the complete NS2 were replaced by the corresponding... |
|
|
US20110014228 |
IL23 MODIFIED VIRAL VECTOR FOR RECOMBINANT VACCINES AND TUMOR TREATMENT
The present invention relates to recombinant replicable viral vectors and viruses which are modified with IL23. This IL23 modified virus is highly immunogenic and attenuated for neurotropic... |